The Hetero Ring Has At Least Seven Members Patents (Class 549/346)
  • Patent number: 9365530
    Abstract: A method of making an anti-Markovnikov addition product is carried out by reacting an acid with an alkene or alkyne in a dual catalyst reaction system to the exclusion of oxygen to produce said anti-Markovnikov addition product; the dual catalyst reaction system comprising a single electron oxidation catalyst in combination with a hydrogen atom donor catalyst. Compositions useful for carrying out such methods are also described.
    Type: Grant
    Filed: May 6, 2013
    Date of Patent: June 14, 2016
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: David A. Nicewicz, David S. Hamilton, Andrew J. Perkowski
  • Publication number: 20150133535
    Abstract: Provided herein, inter alia, are anticancer polyketides. The uses of the polyketides described herein include treatment of cancer, for example, through regulation of the spliceosome and detection of spliceosome inhibition.
    Type: Application
    Filed: September 26, 2014
    Publication date: May 14, 2015
    Inventors: Michael D. Burkart, James J. La Clair, Brian D. Jones, Alexander Mandel, Reymundo Villa, Januario E. Castro, Manoj Kumar Kashyap, Deepak Kumar
  • Publication number: 20150133680
    Abstract: A method of making an anti-Markovnikov addition product is carried out by reacting an acid with an alkene or alkyne in a dual catalyst reaction system to the exclusion of oxygen to produce said anti-Markovnikov addition product; the dual catalyst reaction system comprising a single electron oxidation catalyst in combination with a hydrogen atom donor catalyst. Compositions useful for carrying out such methods are also described.
    Type: Application
    Filed: May 6, 2013
    Publication date: May 14, 2015
    Inventors: David A. Nicewicz, David S. Hamilton, Andrew J. Perkowski
  • Patent number: 9006467
    Abstract: The present invention relates to 1,2,3-triazole containing artemisinin compounds and process for preparation thereof. Described herein is the synthesis, bioassay results and usefulness of the artemisinin derived compounds resulting from 1,3-dipolar cycloaddition reaction of artemisinin derived azide or alkyne with aliphatic or aromatic diazides. These 1,2,3-triazole containing artemisinin derived compounds embodied in this document are found to be active against various cancer cell-lines.
    Type: Grant
    Filed: February 14, 2012
    Date of Patent: April 14, 2015
    Assignee: Councel of Scientific & Industrial Research
    Inventors: Bishwajit Saikia, Nabin C. Barua, Partha P. Saikia, Abhishek Goswami, Paruchuri G. Rao, Ajit K. Saxena, Nitasha Suri
  • Publication number: 20150087829
    Abstract: The present invention relates to compounds of formula I wherein RS denotes F or CF3, Ra denotes H or C1-4-alkyl and Z denotes a leaving group or an optionally substituted or protected hydroxyl group, suitable as intermediates in the synthesis of indanyloxydihydrobenzofuranylacetic acids, which are GPR40 agonists, to a process for preparing these intermediates and to the process for preparing the GPR40 agonists making use of an asymmetric catalytic hydrogenation reaction in the presence of a transition metal catalyst and a chiral auxiliary.
    Type: Application
    Filed: September 24, 2014
    Publication date: March 26, 2015
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Georg DAHMANN, Holger WAGNER, Matthias ECKHARDT, Markus FRANK, Marco SANTAGOSTINO, Juergen SCHNAUBELT, Uwe STERTZ, Thorsten PACHUR
  • Patent number: 8957056
    Abstract: In one aspect, the present invention provides a method for treating colon and/or ovarian cancer in a subject comprising administering to a subject in need thereof a compound of general formula (I): wherein R1-R6, R, -R, Q, Y1, Y2 and n are as defined herein, wherein the compound is present in an amount effective to inhibit colon and/or ovarian tumor metastasis.
    Type: Grant
    Filed: May 25, 2005
    Date of Patent: February 17, 2015
    Assignee: Sloan-Kettering Instiute for Cancer Research
    Inventors: Samuel J. Danishefsky, Christoph Gaul, Jón T. Njardarson, Malcolm A. S. Moore, Kaida Wu, David C. Dorn, Mihirbaran Mandal
  • Publication number: 20140243404
    Abstract: This disclosure is related to halonium compounds useful for cyclization of polyenes, alkenoic acids, and alkenyl alkyl ethers, and halogenation of aromatic compounds. The synthesis of such halonium compounds, compounds made using such halonium compounds, and synthesis of natural compounds, including decalins, using the halonium compounds is also disclosed.
    Type: Application
    Filed: September 13, 2011
    Publication date: August 28, 2014
    Applicant: The Trustees of Columbia University in the City of New York
    Inventors: Scott Alan Snyder, Daniel S. Treitler, Alexandria P. Brucks, Andreas Gollner, Maria I. Chiriac, Nathan E. Wright, Jason J. Pflueger, Steven P. Breazzano
  • Publication number: 20140187588
    Abstract: The disclosure relates to macrocyclic picolinamides of Formula (I) and to the use of these compounds as fungicides.
    Type: Application
    Filed: December 27, 2013
    Publication date: July 3, 2014
    Inventors: Rebecca Lalonde, Kevin G. Meyer, Fangzheng Li, Jeremy Wilmot, Karla Bravo-Altamirano, Chenglin Yao, Iain O'Callaghan, Jessica Herrick, Kyle DeKorver, Yu Lu
  • Patent number: 8703977
    Abstract: The present disclosure provides optionally substituted seven-membered ring isomers of naturally occurring carbohydrate compounds, methods of synthesizing these compounds, intermediate compounds, methods of synthesizing the intermediate compounds, and the like.
    Type: Grant
    Filed: December 30, 2009
    Date of Patent: April 22, 2014
    Assignee: Emory University
    Inventors: Matthew A. Boone, Frank E. McDonald
  • Publication number: 20140088158
    Abstract: The present invention relates to compounds of the formula I, wherein A, Y, Z, R20 to R22 and R50 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they are inhibitors of the endothelial differentiation gene receptor 2 (Edg-2, EDG2), which is activated by lysophosphatidic acid (LPA) and is also termed as LPA1 receptor, and are useful for the treatment of diseases such as atherosclerosis, myocardial infarction and heart failure, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.
    Type: Application
    Filed: November 27, 2013
    Publication date: March 27, 2014
    Applicant: SANOFI
    Inventors: Josef PERNERSTORFER, Heinz-Werner KLEEMANN, Matthias SCHAEFER, Alena SAFAROVA, Marcel PATEK
  • Publication number: 20140024705
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Application
    Filed: April 6, 2012
    Publication date: January 23, 2014
    Applicant: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
    Inventors: Samuel J. Danishefsky, Joan Massague, Manuel Valiente Cortes, Thordur Oskarsson, Malcom Moore, Nicolas Lecomte, Ouathek Ouerfelli, Guangli Yang
  • Patent number: 8563779
    Abstract: A description is given of (4-trifluoromethyl-3-thiobenzoyl)cyclohexanediones of the formula (I) and of their use as herbicides. In this formula (I), X, R1, R2, R3, and R4 are radicals such as hydrogen and organic radicals such as alkyl. A and Z are oxygen or alkylene.
    Type: Grant
    Filed: July 19, 2011
    Date of Patent: October 22, 2013
    Assignee: Bayer CropScience AG
    Inventors: Hartmut Ahrens, Andreas Van Almsick, Elmar Gatzweiler, Dieter Feucht, Isolde Haeuser-Hahn, Stefan Lehr, Christopher Hugh Rosinger
  • Publication number: 20130224136
    Abstract: Compounds that function, alone or in combination, as inhibitors of pigmentation for the improvement of mammalian skin are described herein. Specifically, the compounds of the present disclosure, namely chiral, non-racemic compounds, function as pigment formation inhibitors thereof to beautify skin and discourage the production of melanins. One or more products, consumer and otherwise, comprising the chiral, non-racemic compounds are disclosed herein. Methods of employing both the compounds of the present disclosure and the products incorporating the present compounds are also disclosed herein.
    Type: Application
    Filed: January 4, 2013
    Publication date: August 29, 2013
    Applicant: LASYA, INC.
    Inventor: Lasya, Inc.
  • Publication number: 20130150390
    Abstract: A therapeutic or prophylactic agent for allergic dermatitis is disclosed. The therapeutic or prophylactic agent comprises as an effective ingredient a glycine derivative having a specific structure or a pharmaceutically acceptable salt thereof, for example, the below-described compound [(E)-2-(2,6-dichlorobenzamido)-5-[4-(isopropyl-pyrimidin-2-ylamino)phenyl]pent-4-enoic acid]. The therapeutic or prophylactic agent for allergic dermatitis according to the present invention has high therapeutic or prophylactic effect.
    Type: Application
    Filed: December 12, 2012
    Publication date: June 13, 2013
    Inventors: Mie Kaino, Hiroyuki Meguro
  • Patent number: 8329700
    Abstract: Pyrazine compounds of formula (I): or a pharmaceutically acceptable salt thereof, wherein m, n, p, R1, R2, R3, R4, X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, Y and Z are defined in the specification, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.
    Type: Grant
    Filed: March 7, 2011
    Date of Patent: December 11, 2012
    Assignee: Amgen Inc.
    Inventors: Jennifer R. Allen, Matthew Paul Bourbeau, Ning Chen, Essa Hu, Roxanne Kunz, Shannon Rumfelt
  • Publication number: 20120220780
    Abstract: Disclosed are: a ligand for an asymmetric synthesis catalyst; and a process for producing an ?-alkenyl cyclic compound using the ligand. Specifically disclosed are: a ligand for an asymmetric synthesis catalyst, which is represented by any one of formulae (1) to (4) [wherein R1 represents —Cl or —Br; R2 represents —CH3 or —CF3; and R3 represents —CH2—CH?CH2 or —H]; and a process for producing an ?-alkenyl cyclic compound using the ligand.
    Type: Application
    Filed: October 1, 2010
    Publication date: August 30, 2012
    Applicant: National University Corporation Nagoya University
    Inventors: Masato Kitamura, Shinji Tanaka
  • Publication number: 20120213766
    Abstract: This invention relates to novel compounds with anticancer activity isolated from Vernonia guineensis (Asteraceae) having chemotherapeutic activity against abnormal cell growth such as cancers. The invention also relates to pharmaceutical compositions containing the compounds and to methods of treating abnormal cell growth such as cancer, including combination therapies thereof.
    Type: Application
    Filed: February 22, 2011
    Publication date: August 23, 2012
    Inventors: Ngeh Joseph Toyang, Aloysius Nkwain Toyang, Theresia Ngoin Toyeng
  • Patent number: 8222430
    Abstract: The present invention provides a 1-heterodiene derivative represented by formula (2) or salt thereof: (in formula (2), W represents hydrogen atom or the like, A represents oxygen atom or the like, R1 represents an optionally substituted C1-6 alkyl group or the like, m represents an integer of 0 to 10, n represents an integer of 1 to 4, X1 represents oxygen atom or the like, p represents an integer of 0 to 5, R3 represents an optionally substituted C1-6 alkyl group or the like, r presents an integer of 0 to 5, the 1-heterodiene derivative exists in E-form, Z-form or a mixture thereof according to the carbon-carbon undefined double stereo bond in formula (2)).
    Type: Grant
    Filed: December 17, 2009
    Date of Patent: July 17, 2012
    Assignee: Nippon Soda Co., Ltd.
    Inventors: Koichi Kutose, Jyun Takahashi, Isami Hamamoto, Makio Yano, Jyunko Morohoshi, Jyun Kanazawa
  • Publication number: 20110275839
    Abstract: The present disclosure provides optionally substituted seven-membered ring isomers of naturally occurring carbohydrate compounds, methods of synthesizing these compounds, intermediate compounds, methods of synthesizing the intermediate compounds, and the like.
    Type: Application
    Filed: December 30, 2009
    Publication date: November 10, 2011
    Applicant: EMORY UNIVERSITY
    Inventors: Matthew A. Boone, Frank E. McDonald
  • Publication number: 20110237566
    Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain macrolide compounds (for convenience, collectively referred to herein as “MC compounds”), which, inter alia, are useful in treatment of cancer. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to treat proliferative conditions such as cancer, and in the treatment of diseases and conditions that are mediated by the regulation (e.g. inhibition) of cell proliferation, optionally in combination with another agent.
    Type: Application
    Filed: November 24, 2009
    Publication date: September 29, 2011
    Applicant: MERLION PHARMACEUTICALS PTE LTD
    Inventors: Rustum S. Boyce, Muhammad Sofian Asi Sihombing, Hiroki Sone
  • Patent number: 7999002
    Abstract: The invention relates to the use of a compound of the formula (I) or a pharmaceutically acceptable addition salt thereof for the preparation of a medicament for the prophylaxis and/or treatment of muscular dystrophy.
    Type: Grant
    Filed: August 22, 2006
    Date of Patent: August 16, 2011
    Assignee: Santhera Pharmaceuticals (Schweiz) AG
    Inventors: Thomas Meier, Markus A. Ruegg
  • Patent number: 7956202
    Abstract: Disclosed are novel amino acid derivatives of formula (I) and (II) processes for the preparation thereof, and their use in the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino-[4,5-c]pyrrole.
    Type: Grant
    Filed: December 7, 2009
    Date of Patent: June 7, 2011
    Inventors: Gerardus Johannes Kemperman, Jacobus Johannes Maria Van Der Linden, Michael R. Reeder
  • Publication number: 20110118330
    Abstract: Compounds that inhibit proteolytic enzymes of Human Immunodeficiency Virus (HIV) are described. Preparation of the inhibitors, pharmaceutical compositions containing them, and uses of the compounds or compositions for the treatment of HIV infections are also described.
    Type: Application
    Filed: July 8, 2009
    Publication date: May 19, 2011
    Applicant: PURDUE RESEARCH FOUNDATION
    Inventor: Arun K. Ghosh
  • Publication number: 20110092564
    Abstract: Compositions comprising cyclic amino acids or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier. Said composition are for use in the treatment of pain. Pain includes both acute and chronic forms of pain. The preferred cyclic amino acid is 1-aminocyclobutane-1-carboxylic acid (ACBC).
    Type: Application
    Filed: February 26, 2009
    Publication date: April 21, 2011
    Inventors: Ernest Puil, Bernard A. Macleod, Richard Wall
  • Patent number: 7838691
    Abstract: Organic compounds having Formulas I and II are provided where the variables have the values described herein. Pharmaceutical formulations include the organic compounds or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier can be prepared. Methods of preparing the compounds includes deprotecting protected precursor compounds. Methods of treating cancer or inhibiting ATPase include administering the organic compounds to a subject in need thereof.
    Type: Grant
    Filed: April 4, 2008
    Date of Patent: November 23, 2010
    Assignee: Board of Regents, of the University of Texas System
    Inventors: Jef K. De Brabander, Xin Jiang, Bo Liu
  • Patent number: 7825265
    Abstract: Disclosed herein are novel di-aromatic compounds and methods for using various di-aromatic compounds for treatment and prevention of diseases and disorders related to estrogen receptors.
    Type: Grant
    Filed: November 8, 2005
    Date of Patent: November 2, 2010
    Assignee: ACADIA Pharmaceuticals Inc.
    Inventors: Roger Olsson, Lene Hyldtoft, Fabrice Piu, Magnus Gustafsson, Vladimir Sherbukhin, Birgitte Winther Lund
  • Publication number: 20100233781
    Abstract: Devices, compositions, and methods are described which provide a tubular nanostructure targeted to a lipid bilayer membrane. The targeted tubular nanostructure can have a surface region configured to pass through a lipid bilayer membrane of a cell, a hydrophobic surface region flanked by two hydrophilic surface regions configured to form a pore in a lipid bilayer membrane of a cellular organelle, and at least one ligand configured to bind one or more cognates on the lipid bilayer membrane of the cellular organelle. The target cell can be, for example, a tumor cell, an infected cell, or a diseased cell in a subject. The tubular nanostructure can form a pore in the lipid bilayer membrane of the cellular organelle, e.g., mitochondria, which can permit transit or translocation of at least one compound across the membrane and cause cell death of the target cell.
    Type: Application
    Filed: January 30, 2009
    Publication date: September 16, 2010
    Inventors: Mahalaxmi Gita Bangera, Ed Harlow, Roderick A. Hyde, Muriel Y. Ishikawa, Edward K.Y. Jung, Eric C. Leuthardt, Nathan P. Myhrvold, Dennis J. Rivet, Elizabeth A. Sweeney, Clarence T. Tegreene, Lowell L. Wood, JR., Victoria Y.H. Wood
  • Patent number: 7777076
    Abstract: Macrocyclic compounds of formula (I), in which B1 and X1 taken together are alkylene which is unsubstituted or substituted with ?O and having one CH2 moiety unreplaced or replaced with CH?CH, O, NH or N(alkyl), which inhibit the activity of antiapoptotic Bcl-2 family protein members, compositions containing the compounds and methods of treating diseases during which are expressed one or more than one of an anti-apoptotic family protein member are disclosed.
    Type: Grant
    Filed: May 17, 2006
    Date of Patent: August 17, 2010
    Assignee: Abbott Laboratories
    Inventors: Steven W. Elmore, Christopher L. Lynch, Xilu Wang
  • Publication number: 20100160424
    Abstract: Described are compounds that bind to aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also described are methods of use of the compounds described herein in ameliorating or treating aspartic protease related disorders in a subject in need thereof.
    Type: Application
    Filed: June 20, 2008
    Publication date: June 24, 2010
    Inventors: John J. Baldwin, Salvacion Cacatian, David A. Claremon, Lawrence W. Dillard, Patrick T. Flaherty, Alexey V. Ishchenko, Gerard McGeehan, Robert D. Simpson, Suresh B. Singh, Colin M. Tice, Zhenrong Xu, Jing yuan, Wei Zhao
  • Publication number: 20100113270
    Abstract: Cyclohexanedione compounds of Formula (I) wherein R1 is methyl, ethyl, n-propyl, iso-propyl, cyclopropyl, halomethyl, haloethyl, halogen, vinyl, ethynyl, methoxy, ethoxy, halomethoxy or haloethoxy, R2 and R3 are, independently hydrogen, halogen, C1-C6alkyl, C1-C6haloalkyl, C1-C6alkoxy, C1-C6haloalkoxy, C2-C6alkenyl, C2-C6haloalkenyl, C2-C6alkynyl, C3-C6alkenyloxy, C3-C6haloalkenyloxy, C3-C6alkynyloxy, C3-C6cycloalkyl, C1-C6alkylthio, C1-C6alkylsulfinyl, C1-C6alkylsulfonyl, C1-C6alkylsulfonyloxy, C1-C6haloalkylsulfonyloxy, cyano, nitro, phenyl, phenyl substituted by C1-C4alkyl, C1-C3Cahaloalkyl, C1-C3alkoxy, C1-C3haloalkoxy, cyano, nitro, halogen, C1-C3alkylthio, C1-C3alkylsulfinyl or C1-C3alkylsulfonyl, or heteroaryl or heteroaryl substituted by C1-C3Calkyl, d.
    Type: Application
    Filed: March 7, 2008
    Publication date: May 6, 2010
    Applicant: SYNGENTA CROP PROTECTION, INC.
    Inventors: Christopher John Mathews, John Finney, Louisa Robinson, Melloney Tyte, Michel Muehlebach, Jean Wenger
  • Patent number: 7700584
    Abstract: The present invention provides curcumol derivatives of the following formula (I) or pharmaceutical acceptable salts thereof: wherein, Y is selected from the group consisting of ?CHR2, —CH2R2, ?O, ?—OH or —OR1;R1 is selected from H, R, RCO or HO3S; and R is selected from the group consisting of H; saturated or unsaturated linear C1-10 hydrocarbon group and the like; R2 is selected from the group consisting of F; Cl; Br; I; H; —OH; —OR; —HSO3 and the like; with the proviso that both R1 and R2 are not H. The present invention also provides anti-tumor or antiviral pharmaceutical compositions comprising said derivatives or pharmaceutical acceptable salts thereof. The present invention further provides the use of said derivatives or pharmaceutical acceptable salts thereof in the preparation of a medicament for prophylaxis and/or treatment tumor or an antiviral medicament.
    Type: Grant
    Filed: May 26, 2005
    Date of Patent: April 20, 2010
    Assignee: Hangzhou Minsheng Pharmaceuticals Co., Ltd.
    Inventors: Shulong Wang, Dianwu Guo, Zhaoke Meng
  • Patent number: 7696361
    Abstract: Biomimetic reagents capable of selectively forming non-covalent complexes and initiating intermolecular reactions with peptides in the gas phase are described. The reagents are particularly useful in gas phase peptides chemistry.
    Type: Grant
    Filed: February 18, 2004
    Date of Patent: April 13, 2010
    Assignee: California Institute of Technology
    Inventors: Jesse L. Beauchamp, Ryan R. Julian, Brian M. Stoltz, Jeremy A. May
  • Publication number: 20100069606
    Abstract: Devices, compositions, and methods are described which provide a tubular nanostructure targeted to a lipid bilayer membrane. The targeted tubular nanostructure can have a surface region configured to pass through a lipid bilayer membrane of a cell, a hydrophobic surface region flanked by two hydrophilic surface regions configured to form a pore in a lipid bilayer membrane of a cellular organelle, and at least one ligand configured to bind one or more cognates on the lipid bilayer membrane of the cellular organelle. The target cell can be, for example, a tumor cell, an infected cell, or a diseased cell in a subject. The tubular nanostructure can form a pore in the lipid bilayer membrane of the cellular organelle, e.g., mitochondria, which can permit transit or translocation of at least one compound across the membrane and cause cell death of the target cell.
    Type: Application
    Filed: September 15, 2008
    Publication date: March 18, 2010
    Inventors: Mahalaxmi Gita Bangera, Ed Harlow, Roderick A. Hyde, Muriel Y. Ishikawa, Edward K.Y. Jung, Eric C. Leuthardt, Nathan P. Myhrvold, Dennis J. Rivet, Elizabeth A. Sweeney, Clarence T. Tegreene, Lowell L. Wood, JR., Victoria Y.H. Wood
  • Publication number: 20090227795
    Abstract: A method of measuring the binding activity of a test compound to a splicing factor 3b (SF3b), which comprises the following steps of: (a) contacting a labeled pladienolide compound and a test compound with a cell or a cell fraction; and (b) measuring the distribution of the bound labeled compound. The method enables to screen for a novel active compound capable of acting on (binding to) a pladienolide target molecule or the like.
    Type: Application
    Filed: August 2, 2007
    Publication date: September 10, 2009
    Applicant: Eisai R & D Management Co., Ltd.
    Inventors: Yoshihiko Kotake, Koji Sagane, Takashi Owa, Yoshiharu Mizui, Hajime Shimizu, Yuko Kiyosue
  • Patent number: 7566724
    Abstract: The compounds of the disclosure, for example, the compound represented by the formula: has excellent therapeutic and prophylactic effects against inflammatory bowel disease. Further, they are excellent in absorption and in vivo stability when administered orally in comparison with conventional compounds. That is, the compounds can be administered orally, and can have excellent therapeutic or prophylactic effect sustained for a longer period of time.
    Type: Grant
    Filed: December 22, 2005
    Date of Patent: July 28, 2009
    Assignee: Toray Industries, Inc.
    Inventors: Noriyuki Hirano, Hideki Inoue, Takashi Nagahara, Tomofumi Ohyama, Mie Kaino, Kenichi Hayashi, Sunao Hara, Ryutaro Suzuki
  • Patent number: 7560598
    Abstract: Cyclic ethers or chloroketones useful as fragrance components or intermediates are made by reacting a saturated, tertiary terpene alcohol with hypochloric acid under conditions effective to promote oxidation. trans-Pinanol gives predominantly 6,9-dimethyl-7-oxatricyclo[4.3.0.03,9]-nonane, while cis-pinanol yields almost exclusively 1-acetyl-3-(2-chloroethyl)-2,2-dimethylcyclobutane, a new and versatile intermediate for making cyclobutane derivatives having interesting and diverse aromas.
    Type: Grant
    Filed: April 7, 2006
    Date of Patent: July 14, 2009
    Assignee: Millennium Specialty Chemicals, Inc.
    Inventors: Bernard J. Kane, Mark B. Erman
  • Publication number: 20090110718
    Abstract: New derivatives of tiacumicin B are disclosed and are presented by the general formula: wherein R is The use of these derivatives as a method for treating cancer or tumor is disclosed. A method of treating cancer or tumor by administrating the patient a composition comprising a therapeutically effective amount of the tiacumicin B is also disclosed.
    Type: Application
    Filed: February 25, 2008
    Publication date: April 30, 2009
    Applicant: Echem Hightech Co., Ltd.
    Inventors: Mei-Chiao Wu, Chang-Cheng Huang, Yi-Chen Lu, Wei-Jen Fan
  • Patent number: 7439264
    Abstract: This invention to antagonists that inhibit transporters and receptors. The invention also relates to partial inhibitors of transporters and receptors that allow partial transport or partial binding of a compound to the transporter or receptor. The invention also relates to compounds that differentially prevent transport or binding through a transporter or to a receptor. The invention also relates to the use of these compounds for treating certain diseases and disorders.
    Type: Grant
    Filed: February 10, 2003
    Date of Patent: October 21, 2008
    Assignees: President and Fellows of Harvard College, Organix, Inc.
    Inventors: Peter C. Meltzer, Bertha K. Madras, Paul Blundell, Shanghao Liu
  • Publication number: 20080249162
    Abstract: Organic compounds having Formulas I and II are provided where the variables have the values described herein. Pharmaceutical formulations include the organic compounds or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier can be prepared. Methods of preparing the compounds includes deprotecting protected precursor compounds. Methods of treating cancer or inhibiting ATPase include administering the organic compounds to a subject in need thereof.
    Type: Application
    Filed: April 4, 2008
    Publication date: October 9, 2008
    Inventors: Jef K. DE BRABANDER, Xin Jiang, Bo Liu
  • Publication number: 20080146654
    Abstract: The invention provides polymorphs of a motilide having a structure represented by formula Ia
    Type: Application
    Filed: December 4, 2007
    Publication date: June 19, 2008
    Inventors: Peter J. Licari, Jorge L. Galazzo, Greg O. Buchanan, Alexander Redvers Eberlin, Mark D. Eddleston
  • Publication number: 20080008943
    Abstract: The present invention provides an ink composition comprising a compound having a fragment containing a cyclic ether group having at least one bicyclo or tricyclic substituent.
    Type: Application
    Filed: June 28, 2007
    Publication date: January 10, 2008
    Applicant: FUJIFILM CORPORATION
    Inventor: Kotaro WATANABE
  • Patent number: 7241755
    Abstract: The present invention relates to compounds of the formula in which the variables G, W, Q, X, Y, B1, B2, Z1, Z2, and R1–R7 are as defined herein, methods for the preparation of the derivatives and intermediates thereof.
    Type: Grant
    Filed: August 30, 2006
    Date of Patent: July 10, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Gregory D. Vite, Soong-Hoon Kim, Robert M. Borzilleri, James A. Johnson
  • Patent number: 7214538
    Abstract: The present invention relates to a novel device and method for the detection of lithium ions in a biological fluid. In a preferred embodiment, the present invention provides a novel compound and a optical sensor which incorporates said compound for the detection of lithium ions. Additionally, the present invention provides a method of detecting lithium ions which comprises placing the novel optical sensor into communication with a biological fluid. Once the novel compound of the present invention encounters a lithium ion(s), a fluorescence is generated, the intensity of which is measured and allows for the determination of lithium ion concentration. The present invention provides a medical professional with the ability to selectively determine lithium ion concentration in a biological fluid thereby facilitating the treatment of various diseases, such as manic-depressive illness.
    Type: Grant
    Filed: February 11, 2004
    Date of Patent: May 8, 2007
    Assignees: Worcester Polytechnic Institute, Bayer Health Care, LLC.
    Inventors: John S. Benco, Hubert A. Nienaber, W. Grant McGimpsey
  • Patent number: 7205332
    Abstract: The present invention relates to a new deoxoartemisinin dimer and trimer, which have excellent anticancer activity and lower toxicity and are stable to acids, to a new deoxoartemisinin monomer of intermediate thereof, to preparations thereof, and to anticancer agents comprising the deoxoartemisinin dimer or trimer.
    Type: Grant
    Filed: January 19, 2004
    Date of Patent: April 17, 2007
    Assignee: Industry-Academic Cooperation Foundation, Yonsei University
    Inventor: Man-Kil Jung
  • Patent number: 7094913
    Abstract: The present invention relates to a synthesis of a 7-membered carbocyclic compound having diexomethylene groups, more particularly to a synthesis of a 7-membered carbocyclic compound having diexomethylene groups, a novel compound having the structure represented by the following Chemical Formula 1, from trimethylsilanylmethyl-allenol derivative by the intramolecular Prins cyclization using Lewis acid. The 7-membered carbocyclic compound is a useful intermediate for synthesis of other multicyclic compounds. In Chemical Formula 1, R1 is a C1 to C6 alkyl group, and R2 and R3 is respectively a hydrogen atom, or R1, R2 and R3 may be connected with neighboring substituents to form a 5 to 10-membered aliphatic or aromatic ring.
    Type: Grant
    Filed: April 14, 2004
    Date of Patent: August 22, 2006
    Assignee: Korea Institute of Science and Technology
    Inventors: Yong Seo Cho, Moon Ho Chang, Hun Yeong Koh, Ae Nim Pae, Hyun Jung Kang
  • Patent number: 7053109
    Abstract: The present invention relates to compounds of formula (I): useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal. The compounds of the invention are useful in pharmaceutical compositions and methods of treatment to reduce A beta peptide formation.
    Type: Grant
    Filed: July 10, 2002
    Date of Patent: May 30, 2006
    Assignee: Pharmacia & Upjohn Company
    Inventors: Heinrich Josef Schostarez, Robert Alan Chrusciel
  • Patent number: RE41893
    Abstract: The present invention relates to epothilone derivatives, having the following formula in which the variables G, W, Q, X, Y, B1, B2, Z1, Z2, and R1-R7 are as defined herein, methods for the preparation of the derivatives and intermediates thereof.
    Type: Grant
    Filed: August 11, 2009
    Date of Patent: October 26, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: Gregory D. Vite, Soong-Hoon Kim, Robert M. Borzilleri, James A. Johnson
  • Patent number: RE41895
    Abstract: The present invention relates to epothilone derivatives, having the following formula in which the variables G, W, Q, X, Y, B1, B2, Z1, Z2, and R1-R7 are as defined herein, methods for the preparation of the derivatives and intermediates thereof.
    Type: Grant
    Filed: August 11, 2009
    Date of Patent: October 26, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: Gregory D. Vite, Soong-Hoon Kim, Robert M. Borzilleri, James A. Johnson
  • Patent number: RE41911
    Abstract: The present invention relates to epothilone derivatives, having the following formula in which the variables G, W, Q, X, Y, B1, B2, Z1, Z2, and R1-R7 are as defined herein, methods for the preparation of the derivatives and intermediates thereof.
    Type: Grant
    Filed: August 11, 2009
    Date of Patent: November 2, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: Gregory D. Vite, Soong-Hoon Kim, Robert M. Borzilleri
  • Patent number: RE43003
    Abstract: The present invention relates to compounds of the formula in which the variables G, W, Q, X, Y, B1, B2, Z1, Z2, and R1–R7 are as defined herein, methods for the preparation of the derivatives and intermediates thereof.
    Type: Grant
    Filed: September 15, 2010
    Date of Patent: December 6, 2011
    Assignee: Bristol-Myers Squibb Company
    Inventors: Gregory D. Vite, Soong-Hoon Kim, James A. Johnson